This startup provides data-driven strategies for healthcare businesses, specializing in translating scientific discoveries into diagnostics and therapeutics. They leverage real-time AI and intelligent automation to optimize market access pathways for new healthcare innovations.
Funding
Funding not disclosed
Founders
Product
Problem
Healthcare professionals face challenges in navigating the complex landscape of interconnected diseases to understand biological etiologies and identify potential treatments. Traditional methods often miss novel biological relationships and patterns, hindering the discovery of successful diagnostics and therapies. Integrating heterogeneous data sources and extracting clinically relevant insights from vast amounts of information remains a significant hurdle.
Solution
D&A MedLabs offers AI-powered solutions that leverage knowledge graphs and semantic integration to provide comprehensive biological insights and accelerate the translation of scientific discoveries into diagnostics and therapeutics. The company's technology deciphers evidence from complex infectious, non-transmissible, and chronic diseases by identifying candidate biomarkers and their relationships in disease mechanisms. D&A MedLabs' platform supports the elucidation of molecular processes, enhances the accuracy of clinical decisions, and facilitates drug repurposing strategies. By structuring knowledge and employing smart data strategies, D&A MedLabs enables healthcare specialists to navigate the disease landscape, extract useful insights, and develop successful treatments.
Target Audience
The primary target audience includes healthcare professionals, researchers, and pharmaceutical companies focused on advancing science and translating discoveries into diagnostics and therapies.
Features
- Biomedical knowledge graph leveraging advanced AI to identify novel biological relationships and patterns.
- Proprietary knowledge graphs to leverage semantic integration for advanced reasoning and inference.
- AI-augmented technology for innovative drug repurposing services.
- Disease subtyping identification for personalized approaches to diagnosis, prognosis, and treatment.
- Integration of heterogeneous data sources, including scientific literature, gene descriptions, drug products, patents, clinical trials, and genomic profiles.
- Interoperability enablers for seamless electronic health records integration.
- AI-powered applications to provide intelligent assistance to scientists.